Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8333357 | 0.82 | RAB9A (0.51) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL8333354 | 0.82 | RAB9A (0.51) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL8971679 | 0.82 | — | — | |
| SCHEMBL27574038 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2CA12CA1CA9MEN1 | |
| Hydroxyl Radical SCHEMBL28161121 | 0.80 | RAB9A (0.50) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL1896875 | 0.78 | RAB9A (0.52) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL5414830 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL9395643 | 0.77 | SMN1; SMN2 (0.56) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL1258505 | 0.77 | SMN1; SMN2 (0.50) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL13212895 | 0.77 | LMNA (0.62) | SMN1; SMN2CA12CA1CA9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228525-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | ARBOR PHARMACEUTICALS, LLC | 2021-07-29 | — | — | US | claimed |
| US-9302977-B2 | Method of making monomethyl fumarate | XENOPORT, INC. (US) | 2016-04-05 | — | — | US | claimed |
| EP-2887934-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | XenoPort, Inc. (US) | 2015-07-01 | — | — | EP | claimed |
| EP-2854795-A1 | TREATMENT OF MULTIPLE SCLEROSIS AND PSORIASIS USING PRODRUGS OF METHYL HYDROGEN FUMARATE | XenoPort, Inc. (US) | 2015-04-08 | — | — | EP | claimed |
| US-20140364604-A1 | METHOD OF MAKING MONOMETHYL FUMARATE | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2014-12-11 | — | — | US | claimed |
| US-20140350018-A9 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | XENOPORT, INC. (US) | 2014-11-27 | — | — | US | claimed |
| US-8785443-B2 | Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof | XENOPORT, INC. (US) | 2014-07-22 | — | — | US | claimed |
| EP-2440517-B1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2014-03-26 | — | — | EP | claimed |
| WO-2014031901-A1 | METHODS OF USE FOR MONOMETHYL FUMARATE AND PRODRUGS THEREOF | XENOPORT, INC. (US) | 2014-02-27 | — | — | WO | claimed |
| US-20140057918-A1 | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof | XENOPORT, INC. (US) | 2014-02-27 | — | — | US | claimed |
| WO-2009003911-A1 | THIOPHENE-IMIDAZOPYRIDINES | 4SC AG (DE) | 2009-01-08 | — | — | WO | claimed |
| US-20070225306-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2007-09-27 | — | — | US | claimed |
| CN-1918158-A | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2007-02-21 | — | — | CN | claimed |
| EP-1713806-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2006-10-25 | — | — | EP | claimed |
| WO-2005107760-A1 | COMPOUNDS AND COMPOSITIONS AS INDUCERS OF KERATINOCYTE DIFFERENTIATION | IRM LLC (BM) | 2005-11-17 | — | — | WO | claimed |
| WO-2005080393-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-09-01 | — | — | WO | claimed |
| US-20040204367-A1 | Pipecolic acid derivatives of proline threonine amides useful for the treatment of rheumatoid arthritis | G.D. SEARLE & CO. (US) | 2004-10-14 | — | — | US | claimed |
| US-6613880-B2 | Autoimmune diseases; inflammatory conditions; competitive binding with Human Leukocyte Antigen displacing disease-inducing endogenous peptides | PHARMACIA CORPORATION | 2003-09-02 | — | — | US | claimed |
| US-20010027247-A1 | Pipecolic acid derivatives of proline threonine amides useful for the treatment of rheumatoid arthritis | G.D. SEARLE & CO., (US) | 2001-10-04 | — | — | US | claimed |
| US-5652249-A | ADMINISTERING PYROGLUTAMIDE DERIVATIVE | NIPPON SHINYAKU CO., INC. (JP) | 1997-07-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027247-A1 | Pipecolic acid derivatives of proline threonine amides useful for the treatment of rheumatoid arthritis | ARGLU1, PRR12, PTMS | SMN1; SMN2 4441/4885CA12 1213/4885CA1 515/4885 |
| US-20140057918-A1 | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof | FH, FAH, DHFR | SMN1; SMN2 2493/4885CA12 259/4885CA1 517/4885 |
| US-20070225306-A1 | Compounds and Compositions as Protein Kinase Inhibitors | ABL1, PDGFRA, PDGFRB | SMN1; SMN2 3425/4885CA12 4589/4885CA1 4764/4885 |
| US-20140350018-A9 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | FH, FAH, ALDOA | SMN1; SMN2 1509/4885CA12 481/4885CA1 761/4885 |
| US-20040204367-A1 | Pipecolic acid derivatives of proline threonine amides useful for the treatment of rheumatoid arthritis | ARGLU1, PRR12, PTMS | SMN1; SMN2 4441/4885CA12 1213/4885CA1 515/4885 |
| US-20140364604-A1 | METHOD OF MAKING MONOMETHYL FUMARATE | FH, HNMT, FPGS | SMN1; SMN2 125/4885CA12 2251/4885CA1 594/4885 |
| US-20210228525-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | FH, FAH, ALDOA | SMN1; SMN2 1509/4885CA12 481/4885CA1 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.